Found: 9
Select item for more details and to access through your institution.
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 3, p. 253, doi. 10.1007/s00280-023-04629-1
- By:
- Publication type:
- Article
Masupirdine (SUVN‐502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer's Type: Preliminary Efficacy and Phase‐3 Study Design.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 21, p. 1, doi. 10.1002/alz.074068
- By:
- Publication type:
- Article
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study.
- Published in:
- Neurology & Therapy, 2022, v. 11, n. 4, p. 1583, doi. 10.1007/s40120-022-00390-4
- By:
- Publication type:
- Article
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 9, p. 747, doi. 10.1007/s40261-022-01189-9
- By:
- Publication type:
- Article
Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, v. 8, n. 1, p. 1, doi. 10.1002/trc2.12307
- By:
- Publication type:
- Article
Masupirdine (SUVN‐502): A promising clinical candidate for the management of agitation in Alzheimer's dementia.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.051571
- By:
- Publication type:
- Article
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 5, p. 469, doi. 10.1007/s40261-021-01027-4
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 7, p. 603, doi. 10.1007/s40261-020-00920-8
- By:
- Publication type:
- Article